Malignant fibrous histiocytoma of the breast

Tamir, Gabriel; Nobel, Michael; Hauben, Daniel J.; Sandbank, Judith

doi:10.1016/s0748-7983(95)90732-7

Cited by 30 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast MFH has been reported to account for less than 1% of all primary malignancies of the breast23. In our series, a total of 9 cases of breast MFH are reported, equal to a frequency of 0.2% (9/3981) of breast malignancies treated in our hospital.…”

Section: Discussionmentioning

confidence: 58%

“…The essentiality of axillary lymph node dissection is still unknown. Some reports strongly recommend the procedure214, while others do not3613. In our cohort, 8 patients out of 9 underwent modified radical mastectomy.…”

Section: Discussionmentioning

confidence: 99%

“…The most frequent primary sites of MFH are the lower (49%) and upper (19%) limbs, and the retroperitoneum and abdomen (16%). MFH of the breast is extremely rare, accounting for less than 1% of all breast primary malignancies23. So far, only 65 cases of breast MFH have previously been reported.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma

Qiu

Wei

Huang

et al. 2013

Sci Rep

View full text Add to dashboard Cite

We analyzed the clinicopathological features of 9 breast malignant fibrous histiocytoma (MFH) patients. Immunohistochemistry was used to make both diagnosis and differential diagnosis, and to identify prognostic factors. All tumors lacked epithelial markers but expressed mesenchymal markers, suggesting a mesenchymal origin. Of the five cases expressing Ki-67, two of three patients with axillary lymph node involvement died between 6–8 months, and two died at 17 and 26 months after diagnosis. The two remaining cases, with low Ki-67 expression, had no recurrent or metastatic disease at 145 months after diagnosis. Previous studies have shown that surgery is the primary treatment of choice, but no clear benefit from adjuvant chemotherapy was observed. We demonstrate that axillary lymph node involvement and high expression of Ki-67 are associated with poorer prognosis. A literature review indicates surgery remains the first choice for MFH, but benefits from adjuvant chemotherapy remain unclear.

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma

Qiu

Wei

Huang

et al. 2013

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Malignant fibrous histiocytoma (MFH) is a soft tissue neoplasm with poor prognosis, representing the most common soft tissue sarcoma of middle and late adulthood (1, 2). This tumor occurs most frequently in the lower and upper extremities and retroperitoneum, but the occurrence in the breast is very rare (1).…”

Section: Introductionmentioning

confidence: 99%

Giant Cell Malignant Fibrous Histiocytoma of the Breast: A Case Report

Kim

Hong

et al. 2004

J Korean Med Sci

View full text Add to dashboard Cite

A case of primary malignant fibrous histiocytoma of the breast is reported. The patient was a 48-yr-old woman with a huge tumor involving almost the entire left breast. The central portion of her left breast was already rotted by extensive necrosis and inflammation. She was treated by radical mastectomy and axillary lymphadenectomy to level I. Pathologic examination supported by an immunohistochemical staining confirmed the tumor as malignant fibrous histiocytoma of giant cell type. Axillary lymph nodes were free from tumor metastasis. She had not taken any postoperative adjuvant therapy. The metastasis to lungs was found 2 months after the operation, and she died within 6 months.

show abstract

“…It occurs most often in middle-aged to elderly persons with male predominance (1) and the lower extremity is the most frequent primary site, followed by upper extremity and abdominal cavity or retroperitoneum (2). Although MFH has potential of being found in all organs because of the ubiquitous nature of mesenchymal tissue (5), breast MFH is extremely rare and most of the reports are about primary breast MFH (6,7). According to the most recent WHO classification (2002 edition), soft tissue MFH is considered to be an undifferentiated pleomorphic sarcoma.…”

mentioning

confidence: 99%

Imaging Findings of Metastatic Breast Malignant Fibrous Histiocytoma: A Case Report

Lee

Kang

Kim

et al. 2013

J Korean Soc Magn Reson Med

View full text Add to dashboard Cite

Malignant fibrous histiocytoma (MFH) of the breast is extremely rare and most of the previous reports were focused on the clinicopathological features of breast MFH, so analysis of its imaging findings have been limited. We report a case of MFH involving left breast and left axilla, metastasized from known MFH of left forearm, with focusing on imaging findings based on radiologic evaluation of the breast including mammography, ultrasound and breast MRI.

show abstract

Malignant fibrous histiocytoma of the breast

Cited by 30 publications

References 6 publications

Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma

Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma

Giant Cell Malignant Fibrous Histiocytoma of the Breast: A Case Report

Imaging Findings of Metastatic Breast Malignant Fibrous Histiocytoma: A Case Report

Contact Info

Product

Resources

About